What this page establishes
- GLP-2 is co-secreted with GLP-1 from intestinal L-cells, both cleaved from proglucagon; GLP-2 promotes intestinal growth and absorption and is rapidly degraded by DPP-4.
- Teduglutide (Gattex) is FDA-approved for short bowel syndrome in patients dependent on parenteral support, adults since 2012 and children aged one year and older since 2019.
- Teduglutide is authorised in the EU as Revestive for short bowel syndrome.
- In STEPS, 63% of teduglutide patients vs 30% on placebo reduced parenteral support volume by at least 20% at week 24.
Quick answers
Does GLP-2 cause weight loss?
No. GLP-2 acts on the intestinal lining, not on appetite. In short bowel syndrome the aim is the opposite of weight loss: absorbing more of what you eat.
Read the full answer
The appetite and weight effects people associate with this family come from GLP-1.Can I get teduglutide prescribed for weight loss?
No. It is licensed only for short bowel syndrome with dependence on intravenous nutrition, and its label requires colonoscopy monitoring because it can speed the growth of polyps.
Read the full answer
No trial supports using it for weight.Is GLP-2 the step between GLP-1 and GLP-3?
No. GLP-1 and GLP-2 are separate hormones from one precursor, and GLP-3 is a vendor name for retatrutide rather than a hormone.
Read the full answer
The numbers do not describe a sequence of stronger drugs.
GLP-2 is a real hormone, and that is where its resemblance to GLP-1 mostly ends. Both are cut from the same precursor in the same gut cells, but GLP-1 slows the stomach and quiets appetite, while GLP-2 makes the lining of the small intestine grow and absorb more. The one GLP-2 medicine on the market, teduglutide, is licensed for short bowel syndrome, a rare and serious condition. It is not a weight-loss drug, and nobody prescribes it as one.
What GLP-2 is
When the L-cells lining your lower gut release GLP-1 after a meal, they release GLP-2 alongside it. Both peptides are cleaved from the same parent protein, proglucagon, which is why they share a family name. They then bind different receptors and do different jobs.
GLP-2 acts on the intestine itself. It increases the height of the villi that absorb nutrients, improves blood flow to the gut wall and strengthens the barrier that keeps gut contents where they belong. Natural GLP-2 lasts only minutes in the blood, because the enzyme DPP-4 breaks it down almost immediately.
GLP-1 and GLP-2 side by side
The shared name suggests two versions of one thing. The table shows why that reading is wrong.
| GLP-1 | GLP-2 | |
|---|---|---|
| Made by | L-cells in the gut, from proglucagon | The same L-cells, from the same proglucagon |
| Main job | Raises insulin after meals, slows the stomach, reduces appetite | Grows and repairs the intestinal lining, improves absorption |
| Approved drugs | Semaglutide, liraglutide, dulaglutide and others; tirzepatide also acts here | Teduglutide only |
| Approved for | Type 2 diabetes, obesity, some heart, kidney and liver indications | Short bowel syndrome with dependence on intravenous nutrition |
| Weight loss | Yes, the reason most readers are here | No, and none is claimed on the label |
Teduglutide, the one approved GLP-2 drug
Teduglutide is sold as Gattex in the US and Revestive in Europe. It differs from natural GLP-2 by one amino acid, a change that blocks DPP-4 and lets a once-daily injection work. The FDA approved it in 2012 for adults with short bowel syndrome who depend on parenteral support, meaning nutrition and fluid given into a vein, and later extended it to children from one year old. Europe authorised it the same year.
In the STEPS trial, 63% of patients on teduglutide cut their intravenous support volume by at least 20% at week 24, against 30% on placebo. That is the kind of result GLP-2 produces: fewer hours on a drip, not a lower number on the scale.
The label carries warnings that matter to anyone tempted to use it off-label. Because GLP-2 makes intestinal tissue grow, it can accelerate the growth of existing polyps or tumours, so the label requires a colonoscopy before starting and repeat checks on treatment. It also warns about bowel obstruction, gallbladder and pancreas problems and fluid overload.
Why GLP-1, GLP-2, GLP-3 is not a series
The numbers are not versions. GLP-1 and GLP-2 are two different hormones that happen to come from the same precursor. GLP-3 is neither: no such hormone or receptor exists, and the term is market shorthand for retatrutide, a GIP, GLP-1 and glucagon triple agonist. The full story is on our GLP-3 page.
So if a vendor list puts a GLP-2 product between semaglutide and retatrutide, it is placing a gut-repair drug in a weight-loss lineup. Reasoning from that list, one step up the numbers, leads somewhere the pharmacology does not.
Where GLP-2 does meet weight loss
There is one real overlap, and it is early. Dapiglutide is an investigational drug that activates both GLP-1 and GLP-2 receptors. The GLP-1 arm is there for weight, and the GLP-2 arm is meant to protect the gut. It has been tested in small obesity trials, with a proof-of-concept result published in 2026, and it is approved nowhere.
Longer-acting GLP-2 drugs such as glepaglutide and apraglutide have been through late-stage trials, but for short bowel syndrome, not obesity. None of this makes GLP-2 on its own a weight-loss treatment.
Talk to a clinician before acting on any of this
If you have short bowel syndrome, teduglutide is a specialist decision made with a gastroenterologist and regular colonoscopy. If you are here for weight loss, GLP-2 is the wrong branch of the family. The approved options, and what each trial measured, are on the tiered guide.
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| GLP-2 is co-secreted with GLP-1 from intestinal L-cells, both cleaved from proglucagon; GLP-2 promotes intestinal growth and absorption and is rapidly degraded by DPP-4. | established | Drucker & Yusta, Annu Rev Physiol 2014 |
| Teduglutide (Gattex) is FDA-approved for short bowel syndrome in patients dependent on parenteral support, adults since 2012 and children aged one year and older since 2019. | established | FDA Drugs@FDA (teduglutide) |
| Teduglutide is authorised in the EU as Revestive for short bowel syndrome. | established | EMA EPAR (Revestive) |
| In STEPS, 63% of teduglutide patients vs 30% on placebo reduced parenteral support volume by at least 20% at week 24. | established | Jeppesen et al., Gastroenterology 2012 (STEPS) |
| Dapiglutide, a dual GLP-1/GLP-2 receptor agonist, has been studied for obesity in a randomised proof-of-concept trial published in 2026; it is investigational. | established | EClinicalMedicine 2026 (dapiglutide) |
| Glepaglutide and apraglutide are long-acting GLP-2 analogues tested in clinical trials for short bowel syndrome. | established | ClinicalTrials.gov |
Questions people ask
Is there a drug that combines GLP-1 and GLP-2?
Dapiglutide does, and it is investigational. It has early obesity trial data and no approval anywhere, so the only lawful way to receive it is inside a clinical trial.
Sources
- Drucker & Yusta, Annu Rev Physiol 2014
- FDA Drugs@FDA (teduglutide)
- EMA EPAR (Revestive)
- Jeppesen et al., Gastroenterology 2012 (STEPS)
- EClinicalMedicine 2026 (dapiglutide)
- ClinicalTrials.gov
Keep reading
- GLP-3 Peptide: There Is No Such Drug, and What the Search Really MeansA term invented by the market, answered by nobody who is not selling something.
- Retatrutide: Triple Agonist Phase 3 Results and Current StatusThe strongest weight-loss numbers in obesity medicine, attached to a drug you cannot legally obtain.
- Peptides for Weight Loss: A Tiered Guide to What Is Approved, Pipeline, and Grey MarketThe triage page. Place any compound name into one of three tiers in seconds, with the best trial number and th
- Research-Chemical Peptides: 5-Amino-1MQ and the Grey MarketThe consumer-protection page, built around the cleanest example of a compound with everything except human evi